Blade Therapeutics is advancing innovative anti-fibrotic therapies to meet currently unserved patient needs.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $45M
Founded date: 2015
Investors 3
| Date | Name | Website |
| - | Johns Hopk... | ventures.j... |
| 10.07.2021 | Bay City C... | baycitycap... |
| - | OneVenture... | one-ventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.06.2016 | Series B | $45M | Deerfield ... |
Mentions in press and media 10
| Date | Title | Description |
| 03.01.2022 | Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc. | NEW YORK, Jan. 3, 2022 /PRNewswire/ -- Biotech Acquisition Company (NASDAQ: BIOT) ("BAC"), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confiden... |
| 09.11.2021 | Chamath Palihapitiya-backed Metromile SPAC fails to live up to its promise | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. When SPAC evangelist Chamath Palihapitiya announced his backing of auto-insurance startup Metromi... |
| 25.09.2019 | Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCo and Its Autotaxin Inhibitor (PAT-409) | Link to full release from Blade Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready autotaxin inhibitor... |
| 18.10.2017 | Blade Therapeutics Closes $45M Series B | SOUTH SAN FRANCISCO, CA, Private biopharmaceutical company closed funding of the remaining tranche for a $45 million U.S. Series B financing. >> Click here for more funding data on Blade Therapeutics >> To export Blade Thera... |
| 18.10.2017 | Blade Therapeutics Closes Second Tranche of Series B Financing | Blade Therapeutics, a South San Francisco, CA-based private biopharmaceutical company advancing novel anti-fibrotic therapies, closed its second tranche of Series B financing. The selection of the clinical development candidate triggered fu... |
| 21.08.2017 | MPM-backed Blade Therapeutics Appoints Maria E. Fuentes EVP of research | SAN FRANCISCO–(BUSINESS WIRE)–Blade Therapeutics, a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs, today announced the appointment of Maria E. Fuentes, Ph.D., as Executive Vice Pre... |
| 21.08.2017 | Osage Partners-backed Blade Therapeutics Appoints Maria E. Fuentes EVP of research | SAN FRANCISCO–(BUSINESS WIRE)–Blade Therapeutics, a private biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs, today announced the appointment of Maria E. Fuentes, Ph.D., as Executive Vice Pre... |
| 16.06.2016 | Blade Therapeutics Raises $45M Series B Led by Deerfield Management | Deerfield Management Company today announced its lead investment in the visionary anti-fibrotic company Blade Therapeutics. Blade Therapeutics is developing cutting edge therapies to treat patients with diverse fibrotic diseases for which t... |
| 16.06.2016 | Biopharmaceutical Company Blade Therapeutics Raises up to $45M in Series B Financing | Blade Therapeutics, a South San Francisco, CA-based biopharmaceutical company developing medicines for the treatment of fibrotic disease, raised up to $45m in Series B financing. The round was led by Deerfield Management with participation ... |
| - | Blade Therapeutics Announces Appointment of Jean-Frédéric Viret as Chief Financial Officer | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 22, 2021-- Blade Therapeutics, Inc. (Blade or the Company), a biopharmaceutical company committed to revolutionizing the treatment of fibrotic diseases, today announced the appointment of Je... |